BOARD OF DIRECTORS
Richard Wagner is distinguished in having developed therapeutic platforms spanning the three major therapeutic approaches; nucleic acids, proteins and small molecules. He is a founder and CEO of X-Chem Pharmaceuticals. Prior to founding X-BODY and X-Chem, he was Executive Vice President of Research at Praecis Pharmaceuticals, Inc., where he was an inventor of the DirectSelect small molecule screening technology that led to the creation of a ten billion compound screening library. Praecis was acquired by GlaxoSmithKline in 2007. Prior to joining Praecis, Dr. Wagner co-founded Phylos in 1997 and served as Senior Vice President of Research. At Phylos he was an inventor of a novel class of antibody mimetics which was ultimately acquired by Bristol Myers. Earlier, Dr. Wagner was a founding Director of Cell Biology and a member of the management team at Gilead Sciences, Inc. Dr. Wagner received his BS in Biochemistry from Trinity College and his Ph.D. in Chemistry from Brown University.
Gordon Binder is the former CEO and Chairman of Amgen and currently member of the boards of the American Enterprise Institute, the Massachusetts Institute of Technology and the California Institute of Technology. He was elected a Fellow of the American Academy of Arts and Sciences in 2001. Mr. Binder previously served as the Chairman of BIO and PhRMA.
Brant Binder was the founder and CFO of SRU Biosystems, and a founder of X-Chem Pharmaceuticals. Previously, he served as Vice-President responsible for both domestic and international private equity at Trust Company of the West, where he helped to raise $500 million in equity commitments. Mr. Binder previously held the position of Vice-President at Bankers Trust Company. Mr. Binder received an MBA from the Sloan School at MIT and a BS from Georgetown University's School of Foreign Service.
Julius (Jay) Knowles was most recently Head, Platforms, Strategic Alliances for Novartis, where he headed a team responsible for creating technology-based and drug discovery collaborations, forging a number of major strategic alliances with biotech companies. Previously, Mr. Knowles was founder and President of Novalar Pharmaceuticals, a specialty pharmaceutical company that brought a drug from idea stage through the clinic and on to the market. Prior to this, he was Vice President, Business Development, at Structural Genomix, and Director, Research and Development Planning at Vertex Pharmaceuticals. He has an MBA in Finance from Wharton Business School, an M.Sc. in Chemistry from UC Berkeley, and a BA with Distinction in Chemistry from Carleton College.